PCSK9 in cholesterol metabolism: from bench to bedside

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Pharmacology

Background:

• Dyslipidemia, particularly elevated low-density lipoprotein (LDL) cholesterol, is a major cardiovascular risk factor.
• Statins are first-line therapy but may be inadequate for some patients, including those with familial hypercholesterolemia.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates LDL receptors and is implicated in familial hypercholesterolemia.

Purpose of the Study:

• To explore PCSK9 as a therapeutic target for managing elevated LDL cholesterol.
• To review the efficacy and limitations of current PCSK9 inhibitors.
• To discuss novel PCSK9 inhibition strategies.

Main Methods:

• Review of scientific literature on PCSK9, LDL metabolism, and lipid-lowering therapies.
• Analysis of clinical data for PCSK9 inhibitors (alirocumab, evolocumab).
• Discussion of genetic basis of familial hypercholesterolemia related to PCSK9.

Main Results:

• PCSK9 inhibition effectively lowers plasma LDL levels, even in statin-intolerant or resistant patients.
• Gain-of-function PCSK9 mutations cause familial autosomal dominant hypercholesterolemia.
• Approved PCSK9 inhibitors (alirocumab, evolocumab) are indicated as adjunct therapies for atherosclerotic cardiovascular disease and familial hypercholesterolemia.

Conclusions:

• PCSK9 inhibition represents a significant advancement in managing hyperlipidemia and reducing cardiovascular risk.
• Current PCSK9 inhibitors have drawbacks including cost and administration route.
• Ongoing research aims to develop more accessible and effective PCSK9-targeting therapies.